摘要
胶质瘤为临床常见的原发性中枢神经系统恶性肿瘤,约50%为恶性程度极高的胶质母细胞瘤。传统治疗方法包括外科手术、放射治疗和以替莫唑胺为主的药物化疗,但这些方法均未获得显著延长胶质母细胞瘤患者生存期的效果。目前针对胶质母细胞瘤的标准治疗方案缺乏特异性,肿瘤细胞对放射治疗和烷化剂易产生抵抗,肿瘤复发不可避免,整体预后较差。随着免疫治疗的兴起,目前关于胶质瘤免疫治疗的基础与临床试验方兴未艾,对迄今发表的胶质瘤免疫治疗进展进行综述,有助于了解免疫治疗在胶质瘤综合治疗中的地位和免疫治疗的潜在靶点,以更新治疗策略及阐述免疫治疗耐药的原因。
Glioma is the most common primary tumor of central nervous system(CNS), about 50%of which is extremely malignant glioblastoma(GBM). GBM is the most common primary malignant brain tumors in adults. Surgery, radiotherapy and chemotherapy(most with temozolomide) are regarded as the conventional treatments, but they failed to significantly prolong the survival of GBM patients. The standard treatment of GBM lacks of specificity, and tumor cells are resistant to radiotherapy or alkylating agents, thus recurrence of GBM is inevitably and the overall prognosis is quite poor. Currently, tumor immunotherapy is emerging and booming, which provides more treating options for GBM. This study, hence, reviews the current status of immunotherapy among the comprehensive treatments of glioma, at the same time indicates the potential targets of immunotherapy, further to update treatment strategies and explain the potential for the resistance of immunotherapy.
作者
赵炳昊
王雅宁
周李周
代从新
王裕
马文斌
ZHAO Bing-hao;WANG Ya-ning;ZHOU Li-zhou;DAI Cong-xin;WANG Yu;MA Wen-bin(Department of Neurosurgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China)
出处
《中国现代神经疾病杂志》
CAS
北大核心
2019年第11期807-818,共12页
Chinese Journal of Contemporary Neurology and Neurosurgery
基金
中国医学科学院创新基金资助项目（项目编号：2016-I2M-2-001)~~
